
|Articles|March 1, 2008
Accommodating IOL's new design shows benefits
Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
2
Pickleball, fireworks, eyecare in space, and IRIS registry data among lead stories from day 1 of AAO 2025
3
Ophthalmic innovation by the decades: The 2010s
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5